Secondary hypogammaglobulinaemia (drug-induced)
Low immunoglobulins from medication or protein loss · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Secondary hypogammaglobulinaemia results from drugs (rituximab and other B-cell therapies, anti-epileptics, corticosteroids), protein loss (nephrotic syndrome, protein-losing enteropathy) or malignancy, and can cause recurrent infection. It must be distinguished from primary immunodeficiency and managed by addressing the cause and, where needed, immunoglobulin replacement.
Red flags
- Recurrent or severe bacterial infections
- Persistently low IgG months after rituximab
- Nephrotic-range proteinuria
- Features of underlying myeloma or lymphoma
- Neutropenia compounding infection risk
Assessment
Differential diagnosis
- Common variable immunodeficiency (primary)
- B-cell-depleting therapy effect (rituximab)
- Protein-losing states (nephrotic syndrome, enteropathy)
- Haematological malignancy (myeloma, CLL, lymphoma)
- Anti-epileptic or immunosuppressant drug effect
Investigations
- Serum immunoglobulins and electrophoresis / free light chains
- Medication review (rituximab, anticonvulsants, steroids, mycophenolate)
- Urine protein and albumin (nephrotic range loss)
- FBC and blood film; bone marrow if malignancy suspected
- Vaccine responses and lymphocyte subsets to assess function
Management
- Identify and quantify the degree of immunoglobulin reduction
- Review and, where possible, withdraw or substitute the offending drug
- Investigate for protein loss and underlying haematological malignancy
- Treat acute infections promptly with appropriate antibiotics
- Assess functional antibody responses to decide on replacement
- Start immunoglobulin replacement if recurrent serious infection despite addressing the cause
- Vaccinate (inactivated vaccines) when immune function permits and avoid live vaccines if significantly immunosuppressed
- Monitor immunoglobulin recovery after drug cessation and liaise with immunology
Drugs & doses
Immunoglobulin replacement — IVIG 0.4-0.6 g/kg every 3-4 weeks (or subcutaneous equivalent) if recurrent serious infection
Co-amoxiclav — 625 mg orally three times daily for acute bacterial infection
Prophylactic co-trimoxazole — 480-960 mg orally daily in selected immunosuppressed patients
Pneumococcal and influenza (inactivated) vaccines — per schedule when immune function allows
Disposition
Manage with immunology input; treat the underlying cause and provide replacement or prophylaxis as needed, with admission for serious infection.
Complications & pitfalls
- Recurrent respiratory infections and bronchiectasis
- Severe or opportunistic infection
- Persistent hypogammaglobulinaemia after B-cell therapy
- Delay in recognising underlying malignancy
- Vaccine failure
Exam pearls
- Always review the drug chart — rituximab, anticonvulsants and steroids are common culprits
- Distinguish from primary immunodeficiency by history and recovery after removing the cause
- Check for protein loss and occult malignancy in unexplained low immunoglobulins
- Replacement is warranted when serious infections recur despite treating the cause
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.